Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 11/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 3/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 3/20 | 1.00 |
| ▸ | PARP1 | P09874 | 1/20 | 0.67 |
| ▸ | F2 | P00734 | 7/20 | 0.61 |
| ▸ | F10 | P00742 | 3/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 1/20 | 0.60 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | C1S | P09871 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL427173 | 0.98 | PRSS1 (0.96) | PRSS1PRSS2PRSS3PARP1F2 | |
| Hydrochloric Acid SCHEMBL23541004 | 0.98 | PRSS1 (0.96) | PRSS1PRSS2PRSS3PARP1F2 | |
| Hydrochloric Acid SCHEMBL28548914 | 0.98 | PRSS1 (0.96) | PRSS1PRSS2PRSS3PARP1F2 | |
| SCHEMBL4971524 | 0.82 | PRSS1 (0.69) | PRSS1PRSS2PRSS3PARP1CES2 | |
| SCHEMBL7974185 | 0.82 | F2 (0.75) | PRSS1PRSS2PRSS3F2F10 | |
| SCHEMBL10143566 | 0.81 | PRSS1 (0.68) | PRSS1PRSS2PRSS3PARP1F2 | |
| SCHEMBL283787 | 0.80 | PARP1 (1.00) | PRSS1PRSS2PRSS3PARP1CES2 | |
| SCHEMBL7458676 | 0.80 | PARP1 (0.67) | PRSS1PRSS2PRSS3PARP1CES2 | |
| SCHEMBL2888543 | 0.80 | PARP1 (0.67) | PRSS1PRSS2PRSS3PARP1CES2 | |
| SCHEMBL23235805 | 0.80 | PRSS1 (0.67) | PRSS1PRSS2PRSS3F2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | NEW YORK UNIVERSITY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240150506-A1 | CURING AGENTS FOR FLUOROELASTOMERS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-117529520-A | Fluoroelastomer compositions containing curative | 杜邦特种产品美国有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4305096-A1 | FLUOROELASTOMERS COMPOSITION COMPRISING CURING AGENTS | Dupont Specialty Products USA, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-115532318-B | MOF-supported metal catalyst and preparation method and application thereof | 江南大学 | 2023-07-21 | — | — | CN | disclosed |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-29 | — | — | US | disclosed |
| EP-3883932-B1 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-03-29 | — | — | EP | disclosed |
| CN-115532318-A | MOF-loaded metal catalyst and preparation method and application thereof | 江南大学 | 2022-12-30 | — | — | CN | disclosed |
| WO-2007042806-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | MILLENNIUM PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-7022718-B2 | Pyridine and pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | BOEHRINGER MARKUS (CH) | 2005-06-30 | — | — | US | disclosed |
| US-6867205-B2 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1476435-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068757-A9 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2004-10-07 | — | — | WO | disclosed |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003068757-A1 | NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209092-B2 | Inhibitors of GLI1 as therapeutic agents | GLI1, GLI2, SHH | PRSS1 4261/4885PRSS2 4732/4885PRSS3 4767/4885 |
| US-20030216382-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, G6PC1 | PRSS1 283/4885PRSS2 1024/4885PRSS3 555/4885 |
| US-20230219896-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | PRSS1 3403/4885PRSS2 4367/4885PRSS3 4527/4885 |
| US-20230202983-A1 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | CNR1, CNR2, GPR18 | PRSS1 3403/4885PRSS2 4367/4885PRSS3 4527/4885 |
| US-12595251-B2 | Amidines and amidine analogs for the treatment of bacterial infections and potentiation antibiotics | CLIC1, CBR3, CBR1 | PRSS1 2532/4885PRSS2 3156/4885PRSS3 2796/4885 |
| US-20050143405-A1 | Pyridine and pyrimidine derivatives | DPP4, GPR119, PDXK | PRSS1 217/4885PRSS2 895/4885PRSS3 372/4885 |
| US-20070021472-A1 | N-(5-bromo-2-pyridinyl)-(2-4-[(2-aminosulfonyl)phenyl]phenylcarbonylamino)phenylcarboxamide; potent and highly selective inhibitors; coagulation disorders; antithrombotic agents; diagnostic reagents; good bioavailability and/or solubility | F2, TFPI, PLG | PRSS1 38/4885PRSS2 49/4885PRSS3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.